Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis, Cardiovascular, and Senescence Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SERPINE1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SERPINE1 (PAI-1) Recombinant Protein (Wild-Type & Mutant) HEK293 expressed, High Purity (>95%), Endotoxin Controlled (<1 EU/µg), Sequence Verified. |
View SERPINE1 Products |
| Gene Delivery | SERPINE1 Promise-ORF / Lentivirus Full-length human SERPINE1 ORF for stable cell line construction and overexpression validation. |
View SERPINE1 Products |
| Benchmark Ab | Anti-SERPINE1 Recombinant Biosimilar Antibody Recombinant positive control antibody designed based on clinical-stage neutralizing sequences. |
View SERPINE1 Products |
| Validator | SERPINE1 siRNA Set Target-specific siRNA pool for target knockdown and functional assay validation. |
View SERPINE1 Products |
| Related Target A | PLAT (tPA) Primary physiological target of PAI-1. Essential for executing functional serine protease inhibition assays. |
View PLAT Products |
| Related Target B | VTN (Vitronectin) Physiological stabilizer of active PAI-1. Critical for evaluating inhibitors that disrupt PAI-1/Vitronectin interactions. |
View VTN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Instability (Active to Latent Transition) | Both native wild-type and stable active mutant (14-1b) proteins available to lock target conformation |
| Vitronectin Interference Evaluation | HEK293-expressed, glycosylated SERPINE1 and VTN proteins ensure native-like binding interfaces |
| Lack of Positive Controls | Sequence-verified clinical benchmark antibodies included for assay standardization |
| Off-Target Serpin Screening | Broad panel of related Serpin family proteins (e.g., SERPINF2, SERPINC1) for selectivity profiling |
Live SERPINE1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SERPINE1 (PAI-1) therapeutics is intensifying, with major players shifting focus from traditional systemic anticoagulation to targeted anti-fibrotic and anti-senescence applications. As first-generation small molecule inhibitors progress through clinical trials, the next wave of R&D is targeting highly specific monoclonal antibodies and siRNA therapeutics to treat chronic kidney disease (CKD), idiopathic pulmonary fibrosis (IPF), and age-related metabolic dysfunctions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Renibus Therapeutics, MDI Biological Lab | Acute Kidney Injury (AKI), CKD, Fibrosis | High-throughput screening assays using stable active mutant proteins to prevent target latency. |
| Monoclonal Antibody | Academic institutions, Biotech startups | Oncology, Senescence, Fibrosis | Conformational epitope mapping and Vitronectin-blocking validation using HEK293-expressed antigens. |
| siRNA / RNAi | Alnylam, Arrowhead (Preclinical) | Cardiovascular, Metabolic Diseases | In vitro knockdown verification using sequence-verified siRNA sets and Lentivirus-driven overexpressing lines. |